Ambrx Biopharma Inc.(AMAM) Stock Research - Grey Stern Research
Loading...

Ambrx Biopharma Inc. (AMAM) Stock Analysis

$28.00 (0.07%)

AMAM Financial Performance


Use the table below to view Ambrx Biopharma Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q3 - 2023

Metric Value Ranking among Peers
Price $28.00 -
52 Week Low $6.55 -
52 Week High $28.15 -
Market Cap $1.8 Billion 1/15
Gross Margin 100% 1/15
Profit Margin -100% 13/15
EBITDA margin -47368% 15/15
Q3 - 2023 Revenue $53,000 2/15
Q3 - 2023 Earnings -$23.0 Million 14/15
Q3 - 2023 Free Cash Flow -$19.2 Million 13/15
Trailing 4 Quarters Revenue $3.4 Million 1/15
Trailing 4 Quarters Earnings -$69.4 Million 11/15
Quarterly Earnings Growth -73% 12/15
Annual Earnings Growth 30% 3/15
Quarterly Revenue Growth -98% 15/15
Annual Revenue Growth -44% 15/15
Cash On Hand $225.3 Million 2/15
Short Term Debt $1.9 Million 3/15
Long Term Debt $8.6 Million 4/15

Ambrx Biopharma Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Ambrx Biopharma Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 2/15
PS 514.40 2/15
PB 7.31 2/15
PC 7.87 3/15
Liabilities to Equity 0.12 9/15
ROA -0.26 3/15
ROE -0.29 6/15
Current Ratio 9.33 3/15
Quick Ratio 7.74 3/15
Long Term Debt to Equity 0.04 4/15
Debt to Equity 0.04 5/15
Burn Rate 9.46 2/15
Cash to Cap 0.13 13/15
CCR 0.83 5/15
EV to EBITDA -62.03 15/15
EV to Revenue 452.06 2/15

Company Details

Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers. In addition, it is developing other multiple product candidates targeting immuno-oncology applications, which include ARX822, a fab-small molecule bispecific that is in preclinical development for cancers; and ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the ß and gamma receptors on the cytotoxic T cell. Ambrx Biopharma Inc. has collaborations with Bristol Myers Squibb Company; AbbVie Inc.; BeiGene; Sino Biopharmaceutical Co., Ltd.; NovoCodex; and Elanco Animal Health. The company was incorporated in 2003 and is headquartered in La Jolla, California.

CEO:

Website: https://ambrx.com

Address: 10975 North Torrey Pines Road La Jolla, CA

Exchange: New York Stock Exchange

Industry: Biotechnology

Ambrx Biopharma Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Ambrx Biopharma Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
CohBar, Inc. CWBR $2.6 Million
AVROBIO, Inc. AVRO $62.4 Million
Hepion Pharmaceuticals, Inc. HEPA $7.1 Million
X4 Pharmaceuticals, Inc. XFOR $155.9 Million
CNS Pharmaceuticals, Inc. CNSP $2.3 Million
Sonnet BioTherapeutics Holdings, Inc. SONN $5.7 Million
Inozyme Pharma, Inc. INZY $284.5 Million
Elevation Oncology, Inc. ELEV $197.2 Million
Ocean Biomedical, Inc. OCEA $61.0 Million
Day One Biopharmaceuticals, Inc. DAWN $1.4 Billion
eFFECTOR Therapeutics, Inc. EFTR $9.1 Million
Enveric Biosciences, Inc. ENVB $6.5 Million
Acumen Pharmaceuticals, Inc. ABOS $219.3 Million
Immix Biopharma, Inc. IMMX $65.2 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
AMAM Income Statements
Quarter Year Revenue Earnings
Q3 2023 $ 53,000 -$23.0 Million
Q2 2023 $ 1.1 Million -$17.8 Million
Q1 2023 $ 24,000 -$15.3 Million
Q4 2022 $ 2.2 Million -$13.3 Million
Q3 2022 $ 2.2 Million -$13.3 Million
Q2 2022 $ 1.3 Million -$28.8 Million
Q1 2022 $ 1.6 Million -$22.6 Million
Q4 2021 $ 1.2 Million -$21.2 Million

View All

AMAM Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q3 2023 $225.3 Million $271.5 Million $10.5 Million $242.4 Million
Q2 2023 $228.3 Million $279.9 Million $11.0 Million $250.4 Million
Q1 2023 $149.6 Million $210.6 Million $11.5 Million $182.6 Million
Q4 2022 $55.6 Million $147.0 Million $12.0 Million $117.9 Million
Q3 2022 $55.6 Million $147.0 Million $0 $117.9 Million
Q2 2022 $65.6 Million $180.9 Million $12.6 Million $141.9 Million
Q4 2021 $170.1 Million $229.0 Million $13.1 Million $190.0 Million
Q2 2021 $167.2 Million $213.7 Million $2.4 Million $192.8 Million

View All

AMAM Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q3 2023 -$19.2 Million -$298,000 -$3.0 Million
Q2 2023 -$13.9 Million -$783,000 $78.7 Million
Q1 2023 -$13.0 Million $0 $93.8 Million
Q4 2022 -$12.8 Million -$47,000 $4.5 Million
Q3 2022 -$15.9 Million -$104,000 -$14.6 Million
Q2 2022 -$14.7 Million -$129,000 -$78.0 Million
Q1 2022 -$26.4 Million -$774,000 -$26.4 Million

View All